The FIGHTING FIBROSIS TRIAL is a 12 month, double-blind, placebo-controlled study to evaluate the safety and effectiveness of oral ifetroban in participants with Idiopathic Pulmonary Fibrosis (IPF).

IDIOPATHIC PULMONARY FIBROSIS

Idiopathic Pulmonary Fibrosis (IPF) is a rare disease that causes the air sac tissue in the lungs to become thick and stiff due to unknown causes. There is no cure for IPF. The purpose of this trial is to evaluate the safety and effectiveness of a novel targeted therapy, ifetroban, to help reduce symptoms and progression of lung fibrosis associated with IPF.

PURPOSE OF THE FIGHTING FIBROSIS TRIAL

Fibrosis is the process of replacing normal tissue with scarred tissue which cannot function like normal tissue. Scarring of the lungs is the disease process in IPF. Ifetroban is being studied as a potential anti-fibrotic medication in several diseases but is not approved for and has never been studied in IPF patients. Studies in animal models of IPF showed oral ifetroban can prevent scarring in the lungs associated with IPF and improve survival compared to placebo. You can read more about these studies here.